183 related articles for article (PubMed ID: 12200354)
1. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.
Pulsoni A; Pagano L; Lo Coco F; Avvisati G; Mele L; Di Bona E; Invernizzi R; Leoni F; Marmont F; Mele A; Melillo L; Nosari AM; Pogliani EM; Vignetti M; Visani G; Zagonel V; Leone G; Mandelli F
Blood; 2002 Sep; 100(6):1972-6. PubMed ID: 12200354
[TBL] [Abstract][Full Text] [Related]
2. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
4. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.
Mandelli F; Latagliata R; Avvisati G; Fazi P; Rodeghiero F; Leoni F; Gobbi M; Nobile F; Gallo E; Fanin R; Amadori S; Vignetti M; Fioritoni G; Ferrara F; Peta A; Giustolisi R; Broccia G; Petti MC; Lo-Coco F;
Leukemia; 2003 Jun; 17(6):1085-90. PubMed ID: 12764372
[TBL] [Abstract][Full Text] [Related]
5. Long-term survey of outcome in acute promyelocytic leukemia.
Hu J; Shen Z; Sun H; Wu W; Li X; Sun G; Wang Z
Chin Med J (Engl); 2000 Feb; 113(2):107-10. PubMed ID: 11775530
[TBL] [Abstract][Full Text] [Related]
6. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
[TBL] [Abstract][Full Text] [Related]
7. Does leukocytosis remain a predictive factor for survival outcomes in patients with acute promyelocytic leukemia receiving ATRA plus a chemotherapy-based regimen? A prospective multicenter analysis from TALWG.
Kungwankiattichai S; Owattanapanich W; Rattanathammethee T; Rattarittamrong E; Chanswangphuwana C; Polprasert C; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Prayongratana K; Sriswasdi C; Nakhakes C
Hematology; 2023 Dec; 28(1):2191462. PubMed ID: 36951362
[TBL] [Abstract][Full Text] [Related]
8. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
Lo-Coco F; Avvisati G; Vignetti M; Breccia M; Gallo E; Rambaldi A; Paoloni F; Fioritoni G; Ferrara F; Specchia G; Cimino G; Diverio D; Borlenghi E; Martinelli G; Di Raimondo F; Di Bona E; Fazi P; Peta A; Bosi A; Carella AM; Fabbiano F; Pogliani EM; Petti MC; Amadori S; Mandelli F;
Blood; 2010 Oct; 116(17):3171-9. PubMed ID: 20644121
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute promyelocytic leukaemia using a combination of all-trans retinoic acid and chemotherapy.
Koh LP; Goh YT; Teoh G; Tan P
Ann Acad Med Singap; 2001 Jul; 30(4):401-8. PubMed ID: 11503549
[TBL] [Abstract][Full Text] [Related]
10. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
[TBL] [Abstract][Full Text] [Related]
11. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.
Di Bona E; Avvisati G; Castaman G; Luce Vegna M; De Sanctis V; Rodeghiero F; Mandelli F
Br J Haematol; 2000 Mar; 108(4):689-95. PubMed ID: 10792270
[TBL] [Abstract][Full Text] [Related]
12. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
13. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA; Montesinos P; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte MR; Martínez L; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Vellenga E; Holowiecka A; González-Huerta AJ; Fernández P; De la Serna J; Brunet S; De Lisa E; González-Campos J; Ribera JM; Krsnik I; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Rego EM;
Ann Hematol; 2015 Aug; 94(8):1347-56. PubMed ID: 25975975
[TBL] [Abstract][Full Text] [Related]
14. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Woods WG; Ogden A; Weinstein H; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
Blood; 2002 Dec; 100(13):4298-302. PubMed ID: 12393590
[TBL] [Abstract][Full Text] [Related]
16. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
Tsimberidou AM; Tirado-Gomez M; Andreeff M; O'Brien S; Kantarjian H; Keating M; Lopez-Berestein G; Estey E
Leuk Lymphoma; 2006 Jun; 47(6):1062-8. PubMed ID: 16840198
[TBL] [Abstract][Full Text] [Related]
17. Management of acute promyelocytic leukemia relapse in the ATRA era.
Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
[TBL] [Abstract][Full Text] [Related]
18. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.
Breccia M; Diverio D; Noguera NI; Visani G; Santoro A; Locatelli F; Damiani D; Marmont F; Vignetti M; Petti MC; Lo Coco F
Haematologica; 2004 Jan; 89(1):29-33. PubMed ID: 14754603
[TBL] [Abstract][Full Text] [Related]
19. Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.
Martinelli G; Ottaviani E; Testoni N; Visani G; Diverio D; D'Elia G; Mandelli F; Tura S
Haematologica; 1998 Nov; 83(11):985-8. PubMed ID: 9864917
[TBL] [Abstract][Full Text] [Related]
20. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).
Asou N; Adachi K; Tamura U; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama U; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake H; Ohno R
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S65-71. PubMed ID: 11587370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
